Page header

Recommendation of the President – Kimmtrak (tebentafusp)

On 7 May 2026, the President of the Agency for Health Technology Assessment and Tariff System issued recommendation No. 64/2026 on the inclusion of the medicinal product Kimmtrak (tebentafusp) in the reimbursement program B.163.FM. “Treatment of patients with choroidal melanoma (ICD-10: C69, C69.3, C69.4)”

Publication in Public Information Bulletin (BIP) >>